Atrial Fibrillation in Heart Failure
Steady Progress but Still a Long Way to Go

Bruce S. Stambler, MD; Kenneth R. Laurita, PhD

Management of atrial tachyarrhythmias, especially atrial fibrillation (AF), in patients with congestive heart failure (CHF) remains a major challenge. It is widely recognized that CHF promotes AF and that AF worsens CHF. An individual with either condition who develops the other has higher morbidity and poorer prognosis. The prevalence of AF and CHF is expected to increase as the population ages. Therefore, it remains just as likely as it was more than a decade ago that the emerging epidemic of AF and CHF will continue to be both a challenge and an opportunity.

CHF-induced atrial remodeling plays a significant role in genesis and maintenance of atrial tachyarrhythmias in this setting. Much new information has become available in recent years describing effects of CHF on structural, electrical, and functional properties of atrial tissue, some of which may have important pathophysiological and therapeutic implications.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the University Hospitals Case Medical Center (B.S.S.) and MetroHealth Campus (K.R.L.), Case Western Reserve University, Cleveland, Ohio.

Correspondence to Bruce Stambler, MD, 11100 Euclid Ave, Cleveland, OH 44106. E-mail bss4@cwru.edu

(Circ Arrhythmia Electrophysiol. 2008;1:77-79.)
© 2008 American Heart Association, Inc.

Circ Arrhythmia Electrophysiol is available at http://circcep.ahajournals.org
DOI: 10.1161/CIRCEP.108.785071
there is growing appreciation for calcium-mediated arrhythmogenesis in the failing ventricle. Are we headed down the same path for the atria?

The results presented by Yeh et al suggest a magnitude of calcium dysregulation in the atria similar to that in the ventricles. Notably, reduced cell shortening and triggered activity mediated by DADs in isolated myocytes were demonstrated, suggesting that altered calcium regulation may be a mechanism of atrial mechanical and electrical dysfunction in CHF. The expression and function of calcium regulatory proteins are, however, where differences between the ventricles and atria become apparent. Typically, ventricular calcium transients are smaller and have a slower decay phase in myocytes from failing hearts than in myocytes from normal hearts. In contrast, Yeh et al report that atrial calcium transient amplitude is larger, with a similar decay phase, in cells from canines with CHF as compared with normal cells, even though cell shortening is reduced. As elegantly shown by the authors, the mechanism for reduced cell shortening in the presence of enhanced calcium release probably is due to atrial contractile protein dysfunction attributed to reduced PKA phosphorylation of myosin-binding protein C, an important mediator of contraction. Altered expression of calcium regulatory proteins can explain some of the calcium transient changes, but it’s not obvious whether this is the case. Even though Yeh et al report reduced atrial ryanodine receptor expression in CHF, calcium release is larger than normal. This is probably due to enhanced calcium entry ($I_{Ca,L}$) caused by longer action potentials that increase SR calcium content. Interestingly, SR content was larger in the LA than in the right atrium, which may explain a higher occurrence of ectopy in the LA. Yeh et al also report increased calcium/caldesmon-dependent protein kinase II, which may enhance SR calcium uptake, but SR Ca(2+) ATPase is decreased. This may explain why no significant change in the decay phase of the calcium transient was observed. Calcium/caldesmon-dependent protein kinase II may also contribute to enhanced calcium entry. The authors suggest that enhanced SR calcium content and a reduced expression of calsequestrin promote initiation of DAD-mediated triggered activity. In this CHF model, it is not clear if the ryanodine receptor in the atrium is impaired as in the ventricle. If not, then the mechanisms of DAD activity may be purely calcium overload in the presence of normal ryanodine receptor. Thus, there are ways to explain the contractile and electrical dysfunction on the basis of protein expression; however, the mechanisms of arrhythmogenesis are not exactly the same as in the failing ventricle.

Mechanisms of atrial tachyarrhythmias vary according to the substrate, such as remodeling during rapid atrial rates (ie, AF begets AF) and changes in autonomic tone. In either case, calcium dysregulation may be playing an important role. Atrial remodeling caused by rapid rates can alter calcium-sensitive currents and thus the substrate for AF. Cytosolic calcium as well as atrial ectopy increase during acetylcholine administration after a period of rapid pacing. A novel hypothesis of calcium-mediated triggered activity in the atria has been suggested, whereby the calcium transient far outlasts an acetylcholine-shortened action potential, such that the sodium–calcium exchanger becomes active in the forward mode and depolarizes the membrane. Studies utilizing optical mapping of calcium and voltage in the atria have shown that DADs and triggered activity can be initiated in the LA during autonomic changes and calcium dysregulation can play an important role in arrhythmias originating from the PVs. The extent to which these mechanisms play a role in atrial arrhythmogenesis in the intact, failing heart is not clear, and additional studies are required. In addition to spontaneous ectopy and repetitive activity mediated by triggered activity, calcium dysregulation may also play a role in development of reentrant atrial arrhythmias that are mediated by repolarization alternans. In a canine chronic myocardial infarction model, atrial alternans is enhanced. Therefore, calcium dysregulation in the atrium may promote a broad range of arrhythmia mechanisms.

Also notable in the study by Yeh et al is that isolated CHF atrial myocytes displayed reduced contractility over a range of stimulation frequencies $\geq$2 Hz attributed to alterations in calcium-handling contractile proteins. Pacem-induced CHF also upregulates $\beta$-myosin heavy chain in the LA free wall, which reduces LA contraction velocity in the intact heart as an adaptation to chronic LA pressure and volume overload. In severe CHF, compensatory LA contraction is decreased as a result of increased LV diastolic wall stress and intrinsic LA systolic dysfunction. LA systolic failure contributes to the transition from moderate to advanced CHF. If contractile dysfunction is present in the atria during physiological rates in CHF, what might this imply for patients who develop AF in this setting? During AF, LA contractile function is severely depressed, contributing to reduced cardiac output, decreased exercise capacity, and increased thromboembolism risk. Although intuitively one might expect that restoration of sinus rhythm therefore would improve the adverse hemodynamics associated with AF, this may not always be the case. A small study in patients with AF and CHF who underwent electrical cardioversion found no benefit in peak oxygen consumption, exercise duration, LV size, or neurohormone levels even with maintenance of sinus rhythm after cardioversion. Furthermore, administering AADs that prolong atrial APD theoretically could worsen calcium overload by prolonging atrial repolarization time. Thus, even if sinus rhythm is restored and maintained with current AADs, intrinsic atrial contractile dysfunction and cellular calcium overload may persist. Viewed from this perspective, it may not be entirely surprising that current rhythm control strategies may not benefit patients with AF and CHF. Moreover, this also implies that other therapies (such as ablation) that do not address the underlying atrial contractile dysfunction in CHF may not be associated with sustained improvement in important clinical outcomes.

Treatment of patients with AF in the setting of CHF is no less daunting an endeavor today than it was in the prior century. Despite some important advances in our understanding of the mechanisms that promote CHF-related AF, many questions remain to be answered. More needs to be done to define the culprit mechanisms that promote atrial arrhythmias and contractile dysfunction in CHF and to use these critical insights to develop novel and more effective therapeutic
approaches. The study by Yeh et al and others like it in the future may help to continue the steady progress made thus far and ultimately to lessen the impact of this major source of cardiovascular morbidity and mortality.

Sources of Funding
Dr Stambler has received research grants from the American Heart Association, Pfizer, and CV Therapeutics.

Disclosures
None.

References

Key Words: atrial fibrillation ■ heart failure ■ calcium ■ atrium ■ electrophysiology
Atrial Fibrillation in Heart Failure: Steady Progress but Still a Long Way to Go
Bruce S. Stambler and Kenneth R. Laurita

Circ Arrhythm Electrophysiol. 2008;1:77-79
doi: 10.1161/CIRCEP.108.785071

Circulation: Arrhythmia and Electrophysiology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circep.ahajournals.org/content/1/2/77

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Arrhythmia and Electrophysiology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Arrhythmia and Electrophysiology is online at:
http://circep.ahajournals.org//subscriptions/